Efalizumab: results of a 3-year continuous dosing study for the long-term control of psoriasis

por Leonardi, C, Menter, A, Hamilton, T, Caro, I, Xing, B, Gottlieb, AB
Publicado 2008

Long‐term efficacy and safety of brodalumab in psoriasis through 120 weeks and after withdrawal and retreatment: subgroup analysis of a randomized phase III trial (AMAGINE‐1)

por Papp, K., Menter, A., Leonardi, C., Soung, J., Weiss, S., Pillai, R., Jacobson, A.
Publicado 2020

Network meta‐analysis of biologic treatments for psoriasis using absolute Psoriasis Area and Severity Index values ≤1, 2, 3 or 5 derived from a statistical conversion method

por Mrowietz, U., Warren, R.B., Leonardi, C.L., Saure, D., Petto, H., Hartz, S., Dossenbach, M., Reich, K.
Publicado 2021

Demography, baseline disease characteristics and treatment history of patients with psoriasis enrolled in a multicentre, prospective, disease-based registry (PSOLAR)*

por Kimball, AB, Leonardi, C, Stahle, M, Gulliver, W, Chevrier, M, Fakharzadeh, S, Goyal, K, Calabro, S, Langholff, W, Menter, A
Publicado 2014

Efficacy of risankizumab in patients with moderate‐to‐severe plaque psoriasis by baseline demographics, disease characteristics and prior biologic therapy: an integrated analysis o...

por Strober, B., Menter, A., Leonardi, C., Gordon, K., Lambert, J., Puig, L., Photowala, H., Longcore, M., Zhan, T., Foley, P.
Publicado 2020

Secukinumab demonstrates high sustained efficacy and a favourable safety profile in patients with moderate‐to‐severe psoriasis through 5 years of treatment (SCULPTURE Extension Stu...

por Bissonnette, R., Luger, T., Thaçi, D., Toth, D., Lacombe, A., Xia, S., Mazur, R., Patekar, M., Charef, P., Milutinovic, M., Leonardi, C., Mrowietz, U.
Publicado 2018

Long‐term efficacy of certolizumab pegol for the treatment of plaque psoriasis: 3‐year results from two randomized phase III trials (CIMPASI‐1 and CIMPASI‐2)

por Gordon, K.B., Warren, R.B., Gottlieb, A.B., Blauvelt, A., Thaçi, D., Leonardi, C., Poulin, Y., Boehnlein, M., Brock, F., Ecoffet, C., Reich, K.
Publicado 2020

Long‐term efficacy and safety of risankizumab for the treatment of moderate‐to‐severe plaque psoriasis: interim analysis of the LIMMitless open‐label extension trial beyond 3 years...

por Papp, K.A., Lebwohl, M.G., Puig, L., Ohtsuki, M., Beissert, S., Zeng, J., Rubant, S., Sinvhal, R., Zhao, Y., Soliman, A.M., Alperovich, G., Leonardi, C.
Publicado 2021

Long-term safety of secukinumab in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis: integrated pooled clinical trial and post-mar...

por Deodhar, A., Mease, P. J., McInnes, I. B., Baraliakos, X., Reich, K., Blauvelt, A., Leonardi, C., Porter, B., Das Gupta, A., Widmer, A., Pricop, L., Fox, T.
Publicado 2019

Tildrakizumab efficacy and safety in patients with psoriasis and concomitant metabolic syndrome: post hoc analysis of 5‐year data from reSURFACE 1 and reSURFACE 2

por Fernandez, A.P., Dauden, E., Gerdes, S., Lebwohl, M.G., Menter, M.A., Leonardi, C.L., Gooderham, M., Gebauer, K., Tada, Y., Lacour, J.P., Bianchi, L., Egeberg, A., Pau‐Charles, I., Mendelsohn, A.M., Rozzo, S.J., Mehta, N.N.
Publicado 2022

A head‐to‐head comparison of ixekizumab vs. guselkumab in patients with moderate‐to‐severe plaque psoriasis: 24‐week efficacy and safety results from a randomized, double‐blinded t...

por Blauvelt, A., Leonardi, C., Elewski, B., Crowley, J.J., Guenther, L.C., Gooderham, M., Langley, R.G., Vender, R., Pinter, A., Griffiths, C.E.M., Tada, Y., Elmaraghy, H., Lima, R.G., Gallo, G., Renda, L., Burge, R., Park, S.Y., Zhu, B., Papp, K.
Publicado 2020